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Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have revolutionized the treat
ment landscape of hormone receptor-positive (HR+), human epidermal growth factor recep
tor 2-negative (HER2−) metastatic breast cancer, with an impressive efficacy and safety
profile. Cytopenia is the main adverse event, which is both predictable and manageable.
Here, we report a case of CDK4/6 inhibitor-induced vitiligo-like lesions. Vitiligo or vitiligolike lesions are a rare adverse event; only a few cases are reported in the literature.
Case Presentation: A 71-year-old female patient was diagnosed initially with early-stage
right breast cancer (HR+/HER2−) and was treated with breast-conserving surgery followed
by chemotherapy, radiotherapy, and hormonal therapy. A few years later, she developed
metastatic disease to the hilar lymph nodes, and to multiple skeletal sites, including the left
scapula, left shoulder, left iliac bone, and dorsal vertebrae, for which she was treated with
ribociclib and letrozole. While on treatment, she developed hypopigmented lesions involving
both hands, feet, and face, which were described as vitiligo-like lesions.
Conclusion: CDK4/6 inhibitor-induced vitiligo is a rare and unpredictable adverse event.
This case report highlights the rarity of this adverse event, the dilemma related to the optimal
treatment, and decisions related to continuation, holding, or switching CDK4/6 inhibitors.
Keywords: CDK4/6 inhibitors, ribociclib, vitiligo, vitiligo-like, breast cancer, skin adverse
events
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The cyclin-dependent kinase (CDK) 4/6 inhibitors are novel targeted therapeutic agents
that interrupt the proliferation of malignant cells through the inhibition of cyclin-D/
CDK4/6 complex activity, so that retinoblastoma protein remains hypophosphorylated
and bound to E2F transcription factor and, as a result, blocks cell cycle progression
from G1 to S phase.1,2 These drugs, combined with aromatase inhibitors or fulvestrant,
have revolutionized the treatment landscape of hormone receptor-positive (HR+),
human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer
(mBC). They have provided consistent and impressive efficacy outcomes in various
settings, and combination regimens in first line treatment and beyond, for both pre
menopausal and postmenopausal women.3–7
All three available CDK 4/6 inhibitors – palbociclib, ribociclib, and abemaci
clib – have shown comparable efficacy outcomes, with variable, but predictable and
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manageable adverse events.8 In addition to improving the
time to disease progression, and possibly improving over
all survival,9 quality of life (QoL) is an important outcome
indicator, which is maintained or improved across all
CDK4/6 inhibitor trials.10−13
Bone marrow myelosuppression, mainly neutropenia,
is the most commonly encountered adverse event, and is
probably a class effect, reported in almost 80% of the
studied patients in all clinical trials involving all three
CDK4/6 inhibitors.14–16
A number of mild cutaneous adverse events, such as
low-grade alopecia and skin rash, have been attributed
to CDK4/6 inhibitors.17 More severe skin toxicities are
rare and constitute less than 1% of reported adverse
events.18,19 Vitiligo is a chronic acquired pigmentary
skin disorder, characterized by the absence of pigmen
tary cells from the epidermis that leads to white patches
on the body, usually symmetrically distributed, and is
more obvious in people with dark skin. The lesions are
mostly well-demarcated white patches in different
shapes, and they vary in size from a few millimeters
to centimeters. The initial lesions are most frequently
encountered on the hands, feet, forearms, and face,
favoring a periocular or perioral distribution. The etiol
ogy of vitiligo is unknown, but it is usually associated
with autoimmune disorders, mostly thyroid diseases.
Because of the uncertainty of its etiology, its natural
course and the absence of effective treatment, there is
a sense of social stigmatization, psychological distress,
and low self-esteem among affected patients.
Vitiligo or vitiligo-like lesions are rarely reported
with CDK4/6 inhibitors.20 It is proposed that this
adverse event may be due to the apoptotic effect of
CDK4/6 inhibitors on melanocytes, which may result
in reduced numbers and survival of melanocytes, and,
consequently, the appearance of hypopigmented
lesions.21

Methods
Following the identification of our case, all published
clinical trials, case reports, reviews, and meta-analyses
on the use of CDK4/6 inhibitors, plus aromatase inhibitors
or fulvestrant, were reviewed for reported adverse events.
The literature review was conducted utilizing PubMed,
with the following keywords: CDK4/6 inhibitors, riboci
clib, palbociclib, abemaciclib, vitiligo, vitiligo-like lesions,
breast cancer, and skin adverse events.

6

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/CCID.S344867

DovePress

Case Report
A 71-year-old female patient with thalassemia minor and
hypertension was diagnosed in 1999 with early-stage right
breast cancer. She underwent breast-conserving surgery
and axillary dissection; pathology showed a small tumor,
less than 2 cm, node-negative invasive ductal carcinoma.
Hormone receptors (HRs) were positive but HER2 was
negative. After the surgery, she received chemotherapy
[cyclophosphamide, methotrexate, and 5-fluorouracil
(CMF)] followed by radiotherapy and adjuvant tamoxifen
for 5 years. She did well and was very adherent to clinical
and mammographic follow-up until 2015, when she had
an intractable cough. Imaging studies showed a left hilar
lesion and multiple osteolytic bone metastases, including
the left scapula, left shoulder, left iliac bone, and the
fourth and seventh dorsal vertebrae. Fine needle aspira
tion from the left hilum, through endobronchial ultra
sound, confirmed breast cancer metastasis. Similarly to
the original tumor, hormone receptors were positive (ER
90%, PR 30%) and HER2 was negative. Therefore, she
was started on endocrine therapy with fulvestrant, which
kept her progression free for 2 years. She was then
switched to exemestane and everolimus; however, this
regimen was discontinued owing to grade II pneumonitis
and prenephrotic range proteinuria. At that time, the
patient was enrolled in a double-blind randomized clinical
trial testing CDK4/6 inhibitors along with aromatase inhi
bitors. A few months later, the patient was taken off the
study owing to disease progression, and was found to be
on the placebo arm. Following the US Food and Drug
Administration (FDA) approval of CDK4/6 inhibitors,
she was started on ribociclib and letrozole, which she
tolerated relatively well. Nonetheless, because of persis
tent neutropenia, the dose of ribociclib was reduced to
400 mg daily; on days 1–21 of a 28-day cycle.
Almost 20 weeks after starting ribociclib and letrozole,
she noticed small, rounded, well-demarcated hypopigmen
ted lesions over both hands with expanding patches reach
ing up to the mid forearms (Figure 1). Three weeks later,
new similar lesions started to appear over her face
(Figure 2) and feet. The patient had no personal or family
history of autoimmune diseases. The patient was seen at
the dermatology clinic and was offered treatment with
topical immunomodulators (calcineurin inhibitors), which
she refused, and was kept on topical steroids with little
improvement.
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Figure 2 Vitiligo-like lesions over the face. Depigmented patches surrounded by
normal skin. The patches are whitish in color and are well demarcated.

Figure 1 Well-demarcated, hypopigmented lesions over the hands with expanding
patches reaching up to the forearms.

Discussion
Cutaneous adverse events can be a major problem, and
may directly impact the QoL of patients receiving antic
ancer therapy.22,23 A systematic review and meta-analysis
reviewed the risk and incidence of pigmentary lesions, as
adverse events, among 8052 patients treated with targeted
therapy and enrolled in 36 clinical trials. In total, 17.7% of
patients had depigmented skin lesions.24 Imatinib, cabo
zantinib, nivolumab, pazopanib, pembrolizumab, sorafe
nib, and sunitinib appeared to be the most common
culprits.
A wide range of dermatological manifestations, of
varying degree, were reported with CDK4/6 inhibitors
(Table 1). Alopecia, for example, was reported in 33.2%
of patients treated with the combination of ribociclib and
letrozole, compared to 15.5% treated with letrozole alone,
in the MONALEESA-2 trial; and 14.8% with palbociclib
and fulvestrant, compared to 5.8% with fulvestrant alone,
in the PALOMA-3 trial.25 More severe and devastating
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events have been reported; one case of acute bullous skin
rash,26 three cases of Stevens–Johnson syndrome
(SJS),18,27,28 one case of toxic epidermal necrolysis
(TEN),29 one case of histiocytoid Sweet syndrome,30 and
one case of erythema dyschromicum perstans (ashy der
matosis)-like pigmentation.31
The association between cancer and vitiligo has been
previously studied. The risk of melanoma and nonmelanoma skin cancers was significantly lower in
a group of 10,040 Italian patients with vitiligo.32 Several
other studies reached similar conclusions, and similar
trends were also seen with internal organ
carcinomas.33,34 In a retrospective Korean study from
Table 1 Dermatological Manifestations Reported with CDK4/6
Inhibitors
● Alopecia
● Vitiligo
● Acute bullous skin rash
● Stevens–Johnson syndrome (SJS)
● Toxic epidermal necrolysis (TEN)
● Histiocytoid Sweet syndrome
Abbreviation: CDK, cyclin-dependent kinase.
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2019, which included 101,078 patients with vitiligo and
202,156 controls, the incidence of “internal” cancers was
612.9 per 100,000 person-years in patients with vitiligo,
compared to 708.9 per 100,000 person-years (HR, 0.86;
P<0.001) among the controls.35 It is hypothesized that
patients with autoimmune diseases, such as vitiligo, have
higher immune surveillance, which, in turn, targets cancer
development. In contrast, many previous studies had
shown an increased risk of internal malignancy with
other autoimmune diseases, such as systemic lupus and
rheumatoid arthritis.36–39 These conflicting results may be
explained by the different treatment modalities of vitiligo
and other autoimmune diseases.
The increase in the use of immunotherapy to treat
various cancers has led to more attention being paid to
vitiligo. The appearance of vitiligo among cancer patients
on immunotherapy has been associated with favorable
outcomes in melanoma40,41 and renal cell carcinoma.42
However, with the limited number of vitiligo or vitiligolike cases reported after exposure to CDK4/6 inhibitors,
similar conclusions cannot be reached.
To our knowledge, only 18 previous cases of CDK4/6
inhibitor-induced vitiligo-like lesions have been reported in
the literature. Sollena et al, on behalf of the European
Network for Cutaneous ADverse event to Oncologic drugs
(ENCADO) group, reported the largest series of vitiligo-like
lesions associated with CDK4/6 inhibitors used in the treat
ment of 16 patients with mBC at six European university-based
centers.20 The majority of the patients were treated with topical
steroids and/or topical calcineurin inhibitors, with variable
response. The two other cases were reported by Chan et al, in
71- and 54-year-old women; both of them were treated with
ribociclib and letrozole and neither had a personal or familial
history of autoimmune diseases.43 Our case should add to the
knowledge gained from existing case reports in the literature.
First, vitiligo-like skin lesions may be encountered somewhat
late during the course of ribociclib therapy. Second,
a significant response to the usual vitiligo therapy may not
occur, yet continuation of ribociclib is possible as long as
patients are willing to carry on taking it.
We believe that the incidence of ribociclib, and prob
ably the other CDK4/6 inhibitor-induced cutaneous
adverse events, especially vitiligo or vitiligo-like lesions,
is underreported. Physicians tend to pay more attention to
the more serious and dose-limiting toxicities, such as
cytopenia, cardiac dysfunction, and hepatotoxicity.
With the increasing utilization of CDK4/6 inhibitors in
the most common subset of mBC (HR+/HER2−), and their
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recent approval in HER2-positive disease,44 in addition to
the recent efforts to move their use to earlier stages of
breast cancer,45 CDK4/6 inhibitor-induced vitiligo-like
lesions will probably be more commonly encountered.

Conclusions
Ribociclib-induced vitiligo-like lesions are rare, but prob
ably underreported. This case report highlights the rarity
of this adverse event, the dilemma related to the optimal
treatment, and the difficult decisions related to continua
tion, holding, or switching to other CDK4/6 inhibitors.
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